| Expression pattern: |
UP |
| Associated gene: |
HLF |
| Associated microRNA: |
miR-200b-3p |
| Biological function: |
circCHD2 promotes TGF-beta1-induced LX-2 cell proliferation and increases liver fibrosis markers alpha-SMA and Col1A1; circCHD2 knockdown suppresses activated HSC proliferation and reduces alpha-SMA and Col1A1 levels. |
| Molecular mechanism: |
circCHD2 functions as a ceRNA by sponging miR-200b-3p to regulate downstream HLF in liver cirrhosis-related activated HSCs. |
| Biological pathway or process: |
proliferation (promotes); fibrosis (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Western Blot |
| Clinical significance: |
circCHD2 may have potential to be a therapeutic target of liver cirrhosis. |
| Description: |
In this study, circCHD2 was up-regulated in serum from patients with liver cirrhosis and in TGF-beta1-activated LX-2 hepatic stellate cells. Functionally, circCHD2 promoted activated HSC proliferation and fibrosis-marker expression, while circCHD2 knockdown alleviated these effects through the miR-200b-3p/HLF ceRNA axis. The authors propose circCHD2 as a potential therapeutic target for liver cirrhosis. |
| Confidence score: |
0.6521 |